MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study
Authors:
Open Access
- 11 September 2014
- journal article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9) , e107558
Abstract
Promoter methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) gene has been considered a prognostic marker and has become more important in the treatment of glioblastoma. However, reports on the correlation between MGMT and clinical outcomes in Chinese glioblastoma patients are very scarce. In this study, quantitative methylation data were obtained by the pyrosequencing of tumor tissues from 128 GBM patients. The median overall survival (OS) was 13.1 months, with a 1-year survival of 45.3%. The pyrosequencing data were reproducible based on archived samples yielding data for all glioblastomas. MGMT promoter methylation was detected in 75/128 cases (58.6%), whereas 53/128 (41.4%) cases were unmethylated. Further survival analysis also revealed that methylation was an independent prognostic factor associated with prolonged OS but not with progression-free survival (PFS) (p = 0.029 and p = 0.112, respectively); the hazard radios were 0.63 (95% CI: 0.42–0.96) and 0.72 (95% CI: 0.48–1.09), respectively. These data indicated that MGMT methylation has prognostic significance in patients with newly diagnosed high-grade glioblastoma undergoing alkylating agent-based chemotherapy after surgical resection.Keywords
This publication has 31 references indexed in Scilit:
- Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?Clinical Neuropathology, 2012
- MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaPLOS ONE, 2012
- O6‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation and low MGMT‐encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomideCancer, 2012
- Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoterCancer, 2010
- An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imagingNeuroImage, 2010
- MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMANeurology, 2009
- Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyBritish Journal of Cancer, 2009
- Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelJournal of Neuro-Oncology, 2008